Image_2_Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis.tiff
In advanced prostate cancer, access to recent diagnostic tissue samples is restricted and this affects the analysis of the association of evolving biomarkers such as AR-V7 with metastatic castrate resistance. Liquid biopsies are emerging as alternative analytes. To clarify clinical value of AR-V7 detection from liquid biopsies, here we performed a meta-analysis on the prognostic and predictive value of androgen receptor variant 7 (AR-V7) detected from liquid biopsy for patients with prostate cancer (PC), three databases, the Embase, Medline, and Scopus were searched up to September 2021. A total of 37 studies were included. The effects of liquid biopsy AR-V7 status on overall survival (OS), radiographic progression-free survival (PFS), and prostate-specific antigen (PSA)-PFS were calculated with RevMan 5.3 software. AR-V7 positivity detected in liquid biopsy significantly associates with worse OS, PFS, and PSA-PFS (P <0.00001). A subgroup analysis of patients treated with androgen receptor signaling inhibitors (ARSi such as abiraterone and enzalutamide) showed a significant association of AR-V7 positivity with poorer OS, PFS, and PSA-PFS. A statistically significant association with OS was also found in taxane-treated patients (P = 0.04), but not for PFS (P = 0.21) or PSA-PFS (P = 0.93). For AR-V7 positive patients, taxane treatment has better OS outcomes than ARSi (P = 0.01). Study quality, publication bias and sensitivity analysis were integrated in the assessment. Our data show that liquid biopsy AR-V7 is a clinically useful biomarker that is associated with poor outcomes of ARSi-treated castrate resistant PC (CRPC) patients and thus has the potential to guide patient management and also to stratify patients for clinical trials. More studies on chemotherapy-treated patients are warranted.
Systematic Review RegistrationPROSPERO, CRD42021239353.
History
References
- https://doi.org//10.4103/1477-3163.83937
- https://doi.org//10.3390/cancers13184522
- https://doi.org//10.1093/jnci/djx118
- https://doi.org//10.18632/oncotarget.5585
- https://doi.org//10.1172/JCI122819
- https://doi.org//10.1097/JU.0000000000000803
- https://doi.org//10.1016/j.juro.2016.06.094
- https://doi.org//10.1016/j.eururo.2019.04.006
- https://doi.org//10.1038/s41391-020-00309-w
- https://doi.org//10.1111/bju.14792
- https://doi.org//10.1136/bmj.b2700
- https://doi.org//10.1186/1745-6215-8-16
- https://doi.org//10.3389/fonc.2020.562504
- https://doi.org//10.1001/jamaoncol.2015.1341
- https://doi.org//10.1200/JCO.2016.70.1961
- https://doi.org//10.1056/NEJMoa1315815
- https://doi.org//10.1200/JCO.18.01731
- https://doi.org//10.1200/PO.20.00200
- https://doi.org//10.1016/j.ejca.2019.08.005
- https://doi.org//10.3390/cancers11091365
- https://doi.org//10.1016/j.neo.2019.06.002
- https://doi.org//10.1158/1078-0432.CCR-18-1943
- https://doi.org//10.1016/j.eururo.2016.08.012
- https://doi.org//10.1159/000504416
- https://doi.org//10.1016/j.eururo.2019.08.020
- https://doi.org//10.1002/gcc.22824
- https://doi.org//10.1002/pros.23901
- https://doi.org//10.1016/j.euf.2019.04.020
- https://doi.org//10.1016/j.clgc.2021.03.021
- https://doi.org//10.1016/j.euo.2019.08.010
- https://doi.org//10.3390/cells9010203
- https://doi.org//10.1016/j.eururo.2020.06.042
- https://doi.org//10.1158/2159-8290.CD-16-1406
- https://doi.org//10.1002/pros.23501
- https://doi.org//10.1016/j.eururo.2015.07.007
- https://doi.org//10.1158/1078-0432.CCR-16-1070
- https://doi.org//10.1001/jamaoncol.2018.1621
- https://doi.org//10.1016/j.eururo.2016.11.024
- https://doi.org//10.1001/jamaoncol.2016.1828
- https://doi.org//10.1016/j.eururo.2017.07.024
- https://doi.org//10.3390/cancers11070980
- https://doi.org//10.1007/s40291-018-0333-0
- https://doi.org//10.1158/1078-0432.CCR-18-0320
- https://doi.org//10.1002/pros.23710
- https://doi.org//10.12659/MSM.909669
- https://doi.org//10.1016/j.ctrv.2017.04.008
- https://doi.org//10.3390/cells8070688
- https://doi.org//10.18632/oncotarget.4396
- https://doi.org//10.3389/fonc.2020.572590
- https://doi.org//10.1111/and.13642
CC BY 4.0